Contact Us and Subscribe to DEFINITY® Imaging Updates

We are committed to the professional and patient communities we serve. In the spirit of this commitment, we invite ongoing feedback and dialogue.

Corporate Information:
Lantheus
331 Treble Cove Rd.
N. Billerica, MA 01862
Call Toll-Free: 1.800.362.26681.800.362.2668

US Customer Service/Order DEFINITY®:
Monday-Friday 7:30 AM to 6:00 PM ET
Call Toll-Free: 1.800.299.34311.800.299.3431
Fax: 1.978.671.8860
Fax Orders/POs: 1.978.436.7501

DEFINITY® Reimbursement Support:

Call Toll-Free: 1.800.362.26681.800.362.2668
Press Option 3 for Reimbursement Regarding DEFINITY®
Email: reimbursement@lantheus.com

Lantheus cannot guarantee coverage or payment for products or procedures. Payer policies can vary widely and third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding, and payment information.

Adverse Event and Product Quality Complaint Reports:

United States:
Call Toll-Free: 1.800.343.78511.800.343.7851
Press Option 2 for Adverse Events
Press Option 2 for Product Quality Complaints
Fax: 1.978.436.7296
Email: lantheussafety@lantheus.com

Outside the US:
Call Toll-Free: 1.978.667.95311.978.667.9531
Press Option 2 for Adverse Events
Press Option 2 for Product Quality Complaints
Fax: 1.978.436.7296
Email: lantheussafety@lantheus.com

Sales

If you would like a sales representative to contact you, please complete the form below.

DEFINITY® RT (Perflutren Lipid Microsphere) Injectable Suspension

INDICATIONS

Activated DEFINITY® and activated DEFINITY® RT (Perflutren Lipid Microsphere) Injectable Suspension are indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS

Do not administer DEFINITY® and DEFINITY® RT to patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG).

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY® and DEFINITY® RT administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available.

In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren and PEG-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions and/or with pre-existing PEG hypersensitivity [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying conditions.

Patients with sickle cell disease may be at higher risk of painful crisis and DEFINITY® and DEFINITY® RT should be administered with caution.

Please see accompanying full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Customer Service 1.800.299.3431

BACK TO
TOP